Henry Schein (HSIC)
NASDAQHealth CareMedical - DistributionSnapshot 2026-09-04
NASDAQHealth CareMedical - DistributionSnapshot 2026-09-04
Research Workspace
Put HSIC beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Health Care is in expansion. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar under pressure — Maintain mid-single digit EBITDA growth in 2026: EBITDA margin 7.0% vs mid-single digit target.
View ThesisRevenue is growing steadily — about 6% over the past year.
View GrowthRanks among the strongest in its industry on quality — around the top 21%.
View QualityManagement screens strong on capital allocation, earnings delivery, margins.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationModerate volatility — typically moves about 1% a day.
View RiskHSIC's growth trajectory relies on maintaining mid-single-digit EBITDA growth in 2026. Revenue growth was 6.7% year over year, and the latest earnings beat supports this claim. HSIC trades at 17× P/E versus a peer median of 23×, indicating the price reflects less growth than forecasted. A specific risk is the potential credibility hit if HSIC cuts guidance after recently raising it. Peer multiples imply a price about 6% above where it trades. Our read remains intact.
Trailing returns as of 2026-09-04. HSIC is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 17 analysts currently covering HSIC (as of Sep 2026).
Based on 6 Wall Street analysts offering 12-month price targets for HSIC in the last 4 months.
Continue this research
Compare HSIC with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Free account required to save the handoff. No credit card.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| HSIC Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 12 valuation methods, at three horizons. As of 2026-09-04. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Health Care (broad) — fair value, gap to price, and forward P/E.
Compare the value case
Put HSIC next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Reaffirm EPS guidance for 2026
Revised EPS guidance supports growth objectives.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-09-04. EPS is implied from price ÷ P/E. Not investment advice.
Current $89.81
The last 12 months of price, then the range of analyst 12-month targets from today’s $89.81.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Around the middle on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.

Advances: Reaffirm EPS guidance for 2026
Earnings beat supports EPS guidance for 2026.

Advances: Achieve 3% to 5% sales growth in 2026
Surprise sales growth aligns with sales growth objective.
Executive exits may disrupt strategic initiatives.

Advances: Achieve 3% to 5% sales growth in 2026
Steady dental demand supports sales growth objective.
Advances: Maintain mid-single digit EBITDA growth
Savings goal indicates potential for EBITDA growth.

Advances: Reaffirm EPS guidance for 2026
Reaffirming profit forecast strengthens EPS guidance.